Advertisement

Topics

Zynerba’s cannabis-based epilepsy gel fails in phase 2 trial

03:42 EDT 8 Aug 2017 | Pharmaceutical Business Review

Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial.

Original Article: Zynerba’s cannabis-based epilepsy gel fails in phase 2 trial

NEXT ARTICLE

More From BioPortfolio on "Zynerba’s cannabis-based epilepsy gel fails in phase 2 trial"

Quick Search
Advertisement
 

Relevant Topics

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...